BioCryst Pharmaceuticals (NASDAQ:BCRX) Earns Buy Rating from Analysts at TD Cowen

TD Cowen initiated coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research report report published on Wednesday, Marketbeat.com reports. The firm issued a buy rating and a $30.00 price target on the biotechnology company’s stock.

BCRX has been the topic of several other research reports. Wedbush boosted their price target on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an “outperform” rating in a research note on Monday, June 30th. Bank of America boosted their price target on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, July 1st. JMP Securities boosted their price target on shares of BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the stock a “market outperform” rating in a research note on Wednesday. Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 26th. Finally, Evercore ISI reiterated an “in-line” rating and issued a $8.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $19.18.

BioCryst Pharmaceuticals Stock Performance

BCRX opened at $6.63 on Wednesday. BioCryst Pharmaceuticals has a fifty-two week low of $6.00 and a fifty-two week high of $11.31. The firm’s fifty day moving average is $7.84 and its 200 day moving average is $8.64. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of -36.83, a price-to-earnings-growth ratio of 0.78 and a beta of 1.05.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.03 by $0.12. The company had revenue of $163.35 million during the quarter, compared to analysts’ expectations of $149.59 million. The firm’s revenue for the quarter was up 49.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.06) EPS. On average, equities research analysts predict that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current year.

Insider Activity

In other news, Director Theresa Heggie sold 70,000 shares of the company’s stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total transaction of $595,700.00. Following the sale, the director directly owned 65,352 shares in the company, valued at approximately $556,145.52. This represents a 51.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 5.10% of the company’s stock.

Institutional Trading of BioCryst Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC grew its holdings in BioCryst Pharmaceuticals by 1,161.8% during the 1st quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 5,449 shares during the last quarter. SG Americas Securities LLC grew its holdings in BioCryst Pharmaceuticals by 5.2% during the 1st quarter. SG Americas Securities LLC now owns 43,496 shares of the biotechnology company’s stock valued at $326,000 after purchasing an additional 2,146 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in BioCryst Pharmaceuticals by 113.7% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 37,671 shares of the biotechnology company’s stock valued at $283,000 after purchasing an additional 20,043 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in BioCryst Pharmaceuticals during the 1st quarter valued at about $79,000. Finally, Cerity Partners LLC grew its holdings in BioCryst Pharmaceuticals by 203.6% during the 1st quarter. Cerity Partners LLC now owns 36,410 shares of the biotechnology company’s stock valued at $273,000 after purchasing an additional 24,418 shares during the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.